Prosecution Insights
Prosecution Insights
40 pending office actions • 22 art units • 34 examiners • 0 of 40 (0%) have an AI response strategy ready • 55 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 40 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 40 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 17 (42%) |
| §102 only | 4 (10%) |
| §112 only | 6 (15%) |
| No statute on record | 13 (32%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRISTOL, LYNN ANNE | 3 | 63.7% | +39.7% |
| RYAN, DOUGLAS CHARLES | 2 | 40.0% | +48.9% |
| LANDSMAN, ROBERT S | 2 | 81.3% | +12.9% |
| CHASE, CAROL ANN | 2 | 44.6% | +83.5% |
| SANG, HONG | 2 | 54.7% | +61.8% |
| O DELL, DAVID K | 1 | 57.8% | +35.8% |
| ALLEN, MARIANNE P | 1 | 59.8% | +18.5% |
| NESTOR, DONNA MICHELLE | 1 | 57.5% | +43.9% |
| CHONG, YONG SOO | 1 | 43.7% | +41.6% |
| WILLIS, DOUGLAS M | 1 | 82.6% | +19.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18023246 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF DIALYSIS PRURITUS CONTAINING IL-31 ANTAGONIST AS ACTIVE INGREDIENT | LANDSMAN, ROBERT S | 124d overdue |
| 18458292 | THERAPEUTIC AGENT FOR CANCER OF PATIENT WITH DECREASE IN RB1 FUNCTION USING MYT1 INHIBITOR AND CHEMOTHERAPEUTIC AGENT IN COMBINATION, AND TREATMENT METHOD THEREOF | WILLIS, DOUGLAS M | 9d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18541602 | CROSS-SPECIES ANTI-LATENT TGF-BETA 1 ANTIBODIES AND METHODS OF USE | ALLEN, MARIANNE P | 163d overdue |
| 18023246 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF DIALYSIS PRURITUS CONTAINING IL-31 ANTAGONIST AS ACTIVE INGREDIENT | LANDSMAN, ROBERT S | 124d overdue |
| 18608369 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | O DELL, DAVID K | 112d overdue |
| 16692676 | ANTIGEN-BINDING MOLECULE HAVING REGULATED CONJUGATION BETWEEN HEAVY-CHAIN AND LIGHT-CHAIN | BRISTOL, LYNN ANNE | 104d overdue |
| 17144342 | ANTIGEN-BINDING MOLECULE FOR ELIMINATING AGGREGATED ANTIGENS | SANG, HONG | 53d overdue |
| 15734755 | ANTIGEN-BINDING MOLECULE SHOWING CHANGED HALF-LIFE IN CYTOPLASM | CHASE, CAROL ANN | 31d overdue |
| 18480730 | ANTIGEN-BINDING MOLECULE PROMOTING DISAPPEARANCE OF ANTIGENS HAVING PLURALITY OF BIOLOGICAL ACTIVITIES | LANDSMAN, ROBERT S | 26d overdue |
| 18567435 | FORMULATION CONTAINING DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHONG, YONG SOO | 25d overdue |
| Art Unit | Apps |
|---|---|
| 1643 | 7 |
| 1646 | 4 |
| 1647 | 3 |
| 1674 | 3 |
| 1641 | 3 |
| 1635 | 2 |
| 1675 | 2 |
| 1654 | 2 |
| 1621 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18608369 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | O DELL, DAVID K | 1621 | Other | Final Rejection | 112d overdue | Pending | Mar 18, 2024 |
| 18394091 | ANTIGEN-BINDING MOLECULE AND COMBINATION | RYAN, DOUGLAS CHARLES | 1635 | §103 | Non-Final OA | 40d | Pending | Dec 22, 2023 |
| 18541602 | CROSS-SPECIES ANTI-LATENT TGF-BETA 1 ANTIBODIES AND METHODS OF USE | ALLEN, MARIANNE P | 1647 | Other | Final Rejection | 163d overdue | Pending | Dec 15, 2023 |
| 18533622 | METHODS AND COMPOSITIONS COMPRISING A BRAF INHIBITOR AND A MEK INHIBITOR | NESTOR, DONNA MICHELLE | 1627 | Other | Non-Final OA | 4d overdue | Pending | Dec 08, 2023 |
| 18567435 | FORMULATION CONTAINING DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHONG, YONG SOO | 1623 | §103 | Non-Final OA | 25d overdue | Pending | Dec 06, 2023 |
| 18480730 | ANTIGEN-BINDING MOLECULE PROMOTING DISAPPEARANCE OF ANTIGENS HAVING PLURALITY OF BIOLOGICAL ACTIVITIES | LANDSMAN, ROBERT S | 1647 | Other | Non-Final OA | 26d overdue | Pending | Oct 04, 2023 |
| 18458292 | THERAPEUTIC AGENT FOR CANCER OF PATIENT WITH DECREASE IN RB1 FUNCTION USING MYT1 INHIBITOR AND CHEMOTHERAPEUTIC AGENT IN COMBINATION, AND TREATMENT METHOD THEREOF | WILLIS, DOUGLAS M | 1624 | §103 | Non-Final OA | 9d overdue | Pending | Aug 30, 2023 |
| 18346975 | ANTI-HLA-DQ2.5 ANTIBODY AND ITS USE FOR THE TREATMENT OF CELIAC DISEASE | BRISTOL, LYNN ANNE | 1643 | Other | Non-Final OA | 15d overdue | Pending | Jul 05, 2023 |
| 18266665 | METHOD FOR MEASURING RELATIVE fu RATIO BY DYNAMIC ANALYSIS | NGUYEN, NAM P | 1678 | §103 | Non-Final OA | 44d overdue | Pending | Jun 12, 2023 |
| 18023246 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF DIALYSIS PRURITUS CONTAINING IL-31 ANTAGONIST AS ACTIVE INGREDIENT | LANDSMAN, ROBERT S | 1647 | §103 | Non-Final OA | 124d overdue | Pending | Feb 24, 2023 |
| 18020656 | ONE-ARMED ANTIGEN-BINDING MOLECULES AND USES THEREOF | BERHANE, SELAM | 1675 | §102 | Non-Final OA | 13d | Pending | Feb 10, 2023 |
| 18010611 | SITE SPECIFIC NOTCH-ACTIVATING MOLECULE AND USES THEREOF | CHASE, CAROL ANN | 1646 | §103 | Final Rejection | 28d | Pending | Dec 15, 2022 |
| 17992032 | METHOD FOR SEARCHING AND SCREENING FOR TARGET OF ANTI-CANCER AGENT USING NON-HUMAN ANIMAL MODEL HAVING NOG ESTABLISHED CANCER CELL LINE TRANSPLANTED THEREIN | BEHARRY, ZANNA MARIA | 1632 | §103 | Non-Final OA | 91d overdue | Pending | Nov 22, 2022 |
| 17926673 | IMPROVED GRANZYME B VARIANT | PATTERSON, SARAH COOPER | 1675 | §103 | Non-Final OA | 11d overdue | Pending | Nov 21, 2022 |
| 17914855 | IMMUNE ACTIVATING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF | DRISCOLL, MAUREEN VARINA | 1644 | §102 | Non-Final OA | 105d overdue | Pending | Sep 27, 2022 |
| 17914432 | METHOD FOR PRODUCING MULTISPECIFIC ANTIGEN-BINDING MOLECULES | BRISTOL, LYNN ANNE | 1643 | Other | Non-Final OA | 9d overdue | Pending | Sep 26, 2022 |
| 17913899 | CLAUDIN-6 TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF | NICKOL, GARY B | 1643 | — | Non-Final OA | 52d overdue | Pending | Sep 23, 2022 |
| 17897946 | TREATMENTS FOR ATOPIC DERMATITIS | JIANG, DONG | 1674 | §103 | Non-Final OA | 21d | Pending | Aug 29, 2022 |
| 17896758 | PREPARATION CONTAINING TETRACYCLIC COMPOUND AT HIGH DOSE | FUBARA, BLESSING M | 1613 | Other | Non-Final OA | 59d overdue | Pending | Aug 26, 2022 |
| 17797540 | METHODS FOR PRODUCING AND/OR ENRICHING RECOMBINANT ANTIGEN-BINDING MOLECULES | ROONEY, NORA MAUREEN | 1641 | §102 | Non-Final OA | 28d overdue | Pending | Aug 04, 2022 |
| 17788506 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | REYNOLDS, FRED H | 1658 | §103 | Final Rejection | 44d overdue | Pending | Jun 23, 2022 |
| 17787809 | COMPOSITION FOR TRANSLATION, AND METHOD FOR PRODUCING PEPTIDE | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | §103 | Non-Final OA | 87d overdue | Pending | Jun 21, 2022 |
| 17756756 | PACKAGE OPENING SYSTEM | AYALA, FERNANDO A | 3724 | §103 | Non-Final OA | 72d | Pending | Jun 01, 2022 |
| 17773733 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | SABILA, MERCY HELLEN | 1654 | §112 | Non-Final OA | 20d | Pending | May 02, 2022 |
| 17312296 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | D' AMBROSIO, THEA | 1654 | Other | Final Rejection | 24d overdue | Pending | Apr 29, 2022 |
| 17768053 | AN ANTIBODY, A PHARMACEUTICAL COMPOSITION, AND A METHOD | HOWARD, ZACHARY C | 1674 | §112 | Final Rejection | 34d | Pending | Apr 11, 2022 |
| 17716467 | ANTIGEN-BINDING MOLECULE FOR PROMOTING CLEARANCE FROM PLASMA OF ANTIGEN COMPRISING SUGAR CHAIN RECEPTOR-BINDING DOMAIN | LI, RUIXIANG | 1674 | §112 | Final Rejection | 73d overdue | Pending | Apr 08, 2022 |
| 17767742 | METHOD FOR SELECTING, ASSESSING, OR PRODUCING SODIUM LAURYL SULFATE AS RAW MATERIAL FOR PHARMACEUTICAL FORMULATION, OR FORMULATION OR THE LIKE CONTAINING SAME | WEDDINGTON, KEVIN E | 1629 | §103 | Non-Final OA | 14d | Pending | Apr 08, 2022 |
| 17766280 | INHIBITOR OF CELL PROLIFERATION IN OBINUTUZUMAB RESISTANT CD20-POSITIVE CANCER, AND MEDICINAL COMPOSITION, MEDICINE, PRODUCTION, METHOD FOR INHIBITING CELL PROLIFERATION, THERAPEUTIC METHOD, TYPE II ANTI-CD20 ANTIBODY, COMPOUNDS, COMBINATION OF SAME, ENHANCER AND INDUCER, EACH RELATING THERETO | SANG, HONG | 1646 | §102 | Non-Final OA | 29d | Pending | Apr 04, 2022 |
| 17621746 | ANTIGEN BINDING MOLECULES THAT BIND PDGF-B AND PDGF-D AND USES THEREOF | HOPKINS, SAMANTHA LAKE | 1641 | §103 | Non-Final OA | 62d | Pending | Dec 22, 2021 |
| 17616421 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, PROGRAM, AND METHOD FOR PRODUCING ANTIGEN-BINDING MOLECULE OR PROTEIN | PLAYER, ROBERT AUSTIN | 1686 | §103 | Non-Final OA | 27d | Pending | Dec 03, 2021 |
| 17438993 | ANTIGEN-BINDING MOLECULE CONTAINING ANTIGEN-BINDING DOMAIN OF WHICH BINDING ACTIVITY TO ANTIGEN IS CHANGED DEPENDING ON MTA, AND LIBRARY FOR OBTAINING SAID ANTIGEN-BINDING DOMAIN | SKOKO III, JOHN JOSEPH | 1643 | §112 | Non-Final OA | 114d overdue | Pending | Sep 14, 2021 |
| 17438496 | ANTI-HLA-DQ2.5 ANTIBODY | DIBRINO, MARIANNE | 1641 | Other | Non-Final OA | 119d overdue | Pending | Sep 13, 2021 |
| 17417822 | MUTATED tRNA FOR CODON EXPANSION | RYAN, DOUGLAS CHARLES | 1635 | §103 | Non-Final OA | 3d overdue | Pending | Jun 24, 2021 |
| 17290439 | HER2 S310F SPECIFIC ANTIGEN-BINDING MOLECULES | FAUST, AMBER KATHLEEN | 1643 | §112 | Final Rejection | 29d overdue | Pending | Apr 30, 2021 |
| 17262105 | TARGET CELL SPECIFIC CYTOSOL-PENETRATING ANTIGEN-BINDING MOLECULES | STONEBRAKER, ALYSSA RAE | 1642 | Other | Final Rejection | 17d overdue | Pending | Jan 21, 2021 |
| 17144342 | ANTIGEN-BINDING MOLECULE FOR ELIMINATING AGGREGATED ANTIGENS | SANG, HONG | 1646 | §112 | Non-Final OA | 53d overdue | Pending | Jan 08, 2021 |
| 15734755 | ANTIGEN-BINDING MOLECULE SHOWING CHANGED HALF-LIFE IN CYTOPLASM | CHASE, CAROL ANN | 1646 | §103 | Final Rejection | 31d overdue | Pending | Dec 03, 2020 |
| 17058896 | LIGAND-BINDING MOLECULE CONTAINING SINGLE DOMAIN ANTIBODY | EDGINGTONGIORDANO, FRANCESCA | 1643 | Other | Non-Final OA | 38d overdue | Pending | Nov 25, 2020 |
| 16692676 | ANTIGEN-BINDING MOLECULE HAVING REGULATED CONJUGATION BETWEEN HEAVY-CHAIN AND LIGHT-CHAIN | BRISTOL, LYNN ANNE | 1643 | Other | Final Rejection | 104d overdue | Pending | Nov 22, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial